3 Dividend Aristocrats to Buy in July
A July dividend-focused article highlights three S&P Dividend Aristocrats: McDonald’s (MCD) with a ~2.71% yield and Q1 2026 EPS $2.83 on $6.52B revenue; AbbVie (ABBV) with ~2.71% yield, Q1 2026 revenue $15B and raised 2026 adjusted EPS guidance to $14.08–$14.28; and Lowe’s (LOW) with a $1.25 quarterly dividend and FY2026 adjusted EPS guidance $12.25–$12.75.
How this was made
The 30-second read
Why it matters
No single breaking corporate action is presented; the trading relevance is mainly the combination of (1) cited earnings/guidance ranges, (2) macro read-across (food services, housing), and (3) explicit risk framing.
Market read
Useful for income-oriented positioning and ex-date awareness, but not a fresh catalyst beyond the article’s cited datapoints.
What to watch
The article emphasizes dividend streaks and selected macro prints, but provides limited detail on competitive dynamics, cost structure changes, and how guidance assumptions map to downside housing scenarios.
Background
A July income-focused roundup highlighting three Dividend Aristocrats and their yields, dividend streaks, and cited operating/guidance datapoints.
Ticker impact
Article cites Q1 2026 EPS/revenue beats and global comp sales up 4%, framing margin pressure and a ~2.71% yield.
Likely modest support for dip-buying rather than a fresh catalyst-driven repricing.
The article provides specific operating datapoints and valuation context, but it is still a promotional “buy list” with no clearly new disclosure beyond what’s already referenced.
AbbVie is described as replacing Humira with Skyrizi/Rinvoq growth and raised 2026 adjusted EPS guidance to $14.08–$14.28.
Near-term bias to hold/accumulate on dips, with volatility tied to Humira-biosimilar trajectory.
The guidance range and product revenue growth are concrete, but the overall article reads like a curated list rather than a clearly first-time breaking report.
Lowe’s is framed as a housing-cycle play with a dividend step-up to $1.25 and FY2026 adjusted diluted EPS guidance of $12.25–$12.75.
More likely range-bound until housing data improves; dividend provides downside cushion.
The article includes specific dividend/ex-date and macro housing datapoints, but it does not present a new, time-critical corporate event.
Market effects
Reinforces read-through themes: QSR margin sensitivity (MCD), specialty pharma franchise durability (ABBV), and housing-renovation cycle dependence (LOW).
Primarily US-focused consumer/housing and healthcare exposure; limited cross-region implications stated.
Global comp sales growth is cited for MCD, but no broader international policy/market shock is introduced.
Counterpoint
The “Aristocrats to buy” framing may underweight valuation/macro risk: margin pressure (MCD), biosimilar erosion (ABBV), and housing-starts deceleration (LOW) could dominate near-term returns.
Key entities
- equityMcDonald's
Q1 2026 EPS/revenue and global comp sales growth cited; margin pressure and valuation discussed.
- equityAbbVie
Skyrizi/Rinvoq growth and raised 2026 adjusted EPS guidance cited; Humira biosimilar erosion risk noted.
- equityLowe's
Dividend step-up and FY2026 EPS guidance cited; housing-starts weakness flagged as a risk.
